Prime Capital Investment Advisors LLC Reduces Stake in United Therapeutics Corporation $UTHR

Key Points

• Prime Capital Investment Advisors LLC has reduced its stake in United Therapeutics Corporation by 36.9% during the second quarter, now holding 1,203 shares worth approximately $346,000.
• Insider transactions include the sale of 22,500 shares by COO Michael Benkowitz for over $10 million, highlighting significant insider selling activity during the last ninety days.
• The company's stock performance shows a one-year range of $266.98 to $459.48, with a current market cap of $19.85 billion and an average price target of $457.21 from analysts.

Prime Capital Investment Advisors LLC lowered its holdings in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 36.9% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 1,203 shares of the biotechnology company's stock after selling 704 shares during the quarter. Prime Capital Investment Advisors LLC's holdings in United Therapeutics were worth $346,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Chung Wu Investment Group LLC bought a new position in United Therapeutics during the 2nd quarter valued at approximately $29,000. SVB Wealth LLC bought a new position in United Therapeutics during the 1st quarter valued at approximately $32,000. Geneos Wealth Management Inc. increased its position in United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock valued at $45,000 after buying an additional 85 shares in the last quarter. Sound Income Strategies LLC bought a new position in United Therapeutics during the 1st quarter valued at approximately $49,000. Finally, Brooklyn Investment Group increased its position in United Therapeutics by 103.2% during the 1st quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company's stock valued at $59,000 after buying an additional 98 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.

Insider Transactions at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the business's stock in a transaction dated Monday, October 6th. The stock was sold at an average price of $450.24, for a total transaction of $10,130,400.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Christopher Causey sold 1,000 shares of the business's stock in a transaction dated Wednesday, September 24th. The shares were sold at an average price of $440.00, for a total value of $440,000.00. Following the sale, the director directly owned 4,865 shares of the company's stock, valued at $2,140,600. This represents a 17.05% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 261,935 shares of company stock worth $105,561,472. 10.30% of the stock is currently owned by insiders.

United Therapeutics Price Performance

Shares of UTHR opened at $440.00 on Friday. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $459.48. The firm has a market capitalization of $19.85 billion, a P/E ratio of 17.17, a PEG ratio of 6.71 and a beta of 0.66. The business has a fifty day moving average of $372.27 and a 200 day moving average of $323.67.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The firm had revenue of $798.60 million during the quarter, compared to the consensus estimate of $802.13 million. During the same period in the previous year, the firm earned $5.85 EPS. The business's revenue was up 11.7% on a year-over-year basis. Analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on UTHR shares. Royal Bank Of Canada started coverage on United Therapeutics in a research report on Friday, September 26th. They set an "outperform" rating and a $569.00 price objective for the company. Oppenheimer raised their price objective on United Therapeutics from $510.00 to $575.00 and gave the company an "outperform" rating in a research report on Friday, September 5th. Cantor Fitzgerald raised their price objective on United Therapeutics from $405.00 to $525.00 and gave the company an "overweight" rating in a research report on Wednesday, September 10th. Bank of America raised their price objective on United Therapeutics from $314.00 to $463.00 and gave the company a "neutral" rating in a research report on Tuesday, September 2nd. Finally, UBS Group lifted their target price on United Therapeutics from $560.00 to $580.00 and gave the stock a "buy" rating in a report on Monday, September 29th. Ten research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $457.21.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.